Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 6, 2000, Pages 453-459

  Chen, L C ^a,b   Chou, M H ^b   Lin, M F ^b   Yang, Ling Ling ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Chinese medicine; Paeoniae Radix; Valproic acid

Indexed keywords

PAEONIA RADIX; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTEIN BINDING; VALPROIC ACID;

EID: 0034534425     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00313.x     Document Type: Article

References (40)

1. Complementary medicine is booming worldwide
2. Unconventionalmedicine in the United States: Prevalence, cost, and patterns of use
3. Trends in alternative medicine use in the United States 1990-97: Results of a follow-up national survey
4. Use of alternative health carepractitioners by Canadians
5. Prevalence and cost of alternative medicine in Australia
6. Complementary medicine in Europe
7. Advances in treatment of epilepsywith traditional Chinese medicine
8. Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan - A pharmaco-epidemiologic study
9. Valproic acid: Absorption, distribution, and excretion
10. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations
11. A mechanistic approach to antiepileptic drug interactions
12. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
13. Drug interactions in epilepsy
14. Clinical valproate toxicity induced by acetylsalicylic acid
15. Inhibitory effect of peony root extracton pentylenetetrazol-induced EEG power spectrum changes and extracellular calcium concentration changes in rat cerebral cortex
16. Studies on the constituents of Japanese and Chinese crude drugs. VIII. Paeoniflorin; a glucoside of Chinese paeonyroot (1)
17. Studies on active substances in herbs used for Oketsu('stagnant blood') in Chinese medicine. VI. On the anticoagulative principle in Paeoniae Radix
18. Candidates for cognitive enhancer extracted from medicinal plants, Paeniflorin and tetramethylpyrazine
19. Paeoniflorin attenuates learning impairment of aged rats in operant brightness discrimination task
20. Paeony and its major constituent paeoniflorin, improve radial maze performance impaired by scopolamine in rats
21. Negatively regulatory effects of paeoniflorin on immune cells
22. Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora
23. 2+ mobilization in the nerve-stimulated skeletal muscle of mice
24. Depolarizing neuromuscular blocking action induced by electropharmacological coupling in the combined effect of paeoniflorin and glycyrrhizin
25. The electropharmacological mechanisms of depolarizing neuromuscular blocking effects induced by the combination of paeoniflorin and glycyrrhizin
26. Anticonvulsant activity of paeonimetabolin-I adducts obtained by incubation of paeoniflorin and thiol compounds with Lactobacillus brevis
27. Potent anticonvulsant paeonimetabolin-I derivatives obtained by incubation of paeoniflorin and thiol compounds with Lactobacillus brevis
28. Pharmacokinetics andbioavailability of sodium valproate
29. Pharmacokinetics of valproic acid after oral and intravenous administration
30. Pharmacokinetics ofvalproate in adults after a single loading dose
31. Meal-dependent absorption of enteric-coated sodium valproate
32. Anticholinergic action of paeonyroot and its active constituents
33. Valproate: Absorption, distribution, and excretion
34. Disposition of valproic acid in man
35. Valproic acid dosage and plasma protein binding and clearance
36. Valproic acid binding tohuman serum albumin and determination of free fraction in the presence of antiepileptics and free fatty acids
37. Disposition ofvalproic acid in patients with liver disease
38. Proteinbinding of valproic acid in uremic patients
39. Interactionbetween valproic acid and aspirin in epileptic children; serum protein binding and metabolic effects
40. A physiological approach to hepatic drug clearance